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Abstract: The platelet glycoprotein IIb (GPIIb) is an integral membrane protein, which forms with GPIIIa a calcium-
dependent heterodimer. This heterodimer forms in the endoplasmic reticulum (RE) and in the absence of heterodimer 
formation, both GPIIb and GPIIIa are retained and degraded in the ER. Efforts have been previously made to produce 
recombinantly the soluble GPIIb, which can be used in the solid phase assays for the antibody identification. However, 
all previous attempts to produce such a construct have not yield any product. This mini-review describes the previous 
attempts and the future challenges.  
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INTRODUCTION 
The platelet glycoprotein IIb (GPIIb) and IIIa form a 
calcium-heterodimer (Figure 1) on the platelet surface 
that acts as a receptor for fibrinogen and other 
adhesive proteins [1]. The heterodimer is formed in the 
endoplasmic reticulum (ER), undergoes N-linked 
glycosylation, and forms disulfide bonds. The 
glycoproteins are then transported to the Golgi 
apparatus through a process of bulk flow where final 
oligosaccharides processing is completed and 
cleavage of a single-chain pro-GPIIb into mature GPIIb 
is finalized comprising a heavy and light chain [2]. Both 
GPIIb and GPIIIa must be correctly folded and 
assembled to be successfully expressed as a 
heterodimer on the platelet cell surface [3]. The 
production of the recombinant soluble (rs) forms of 
GPIIb and/or GPIIIa is useful to study the structure and 
function of the heterodimer and to use them in the solid 
phase assays to identify the antibodies (Abs) directed 
against the antigens reside on the heterodimer [4]. The 
first group investigating the feasibility of producing the 
rs GPIIIa was Bennett et al. (1993) [5]. However, the 
amount produced was modest, the structural integrity 
has not been evaluated, and the protein was not 
demonstrated to be monomeric [6]. Recently, we have 
demonstrated and for the first time the feasibility of 
producing the rs GPIIIa in a large scale using the 
lentiviral transduction strategy. The rs GPIIIa was also 
suitable for the detection of Abs directed against the 
human platelet antigen 1a (HPA-1a) and HPA-1b, 
which reside on GPIIIa [4]. On the other hand, all 
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The rs GPIIb is retained in the transfected cells, which 
was attributed to the presence of retention signal in the 
extracellular domain of the GPIIb [5]. Better 
understanding of the dynamics of GPIIb/GPIIIa 
formation, better vector design, transduction of various 
normal and cancerous mammalian cells, cultivation of 
transduced cells under different conditions, and many 
other factors may contribute in the future to successful 
production of the soluble form of GPIIb. This mini-
review is an attempt to provide some pathways, which 
might lead in the future to the production of the rs 
GPIIb.  
PHYSIOLOGY OF PLATELET GPIIB/GPIIIA FORMA- 
TION 
Platelets are the smallest (1-2 M) blood cells, 
which are responsible for proper clotting. Glycoprotein 
IIb/IIIa is one of the platelet surface expressed proteins 
that plays a major role in the common pathway of 
platelet aggregation; a cornerstone reaction in 
hemostasis and thrombosis [7]. GPIIb couples to 
GPIIIa at a micromolar concentration of Ca
2+
, 
expressed on human platelets as a heterodimer in an 
apparent 1:1 stoichiometry, and accounts for 18% of 
the platelet plasma membrane protein mass [8]. GPIIb, 
with a molecular weight of an approximately 136,000, 
[8] is produced when its DNA blueprint is copied and 
the code translated into the matching amino acid 
sequence. The linear chain is then modified into a three 
dimensional conformation and folded to couple to 
GPIIIa in the ER. The heterodimer undergoes 
glycosylation and then transported to the Golgi 
apparatus, where the cleavage of the GPIIb occurs. 
The GPIIb is stabilized by chemical forces between the 
heavy and light chains of the GPIIb and the forces 
between the GPIIb and GPIIIa. Because the protein 
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folding problem is still an issue on track for 
investigation [9], it is also still unclear how the 
GPIIb/IIIa achieves its native fold. 
HUMAN PLATELET ALLOANTIGENS EXPRESSED 
ON GPIIB: FREQUENCY AND ASSOCIATED 
DISEASES  
To date, 6 human platelet alloantiges (HPAs) have 
been identified on GPIIb (Table 1). Notwithstanding 
immunization against those antigens is infrequent, fetal 
/ neonatal alloimmune thrombocytopenia (FNIAT) and 
intracranial hemorrhage is usually severe. The epitopes 
expressed on the GPIIb are the second most favored 
targets of antibodies detected in alloimmune platelet 
disorders [10]. HPA-3 system is expressed on GPIIb, 
and is determined by an isoleucine-serine amino acid 
substitution at position 843, and is account for 
approximately 2 percent of FNIAT [11, 12]. Therefore, 
detection of the HPA-3a alloantibodies is required. 
However, it has been shown that their detection can 
been overlooked by the current used assays [13].
 
The 
rest of HPA systems on the GPIIb are also important 
and their corresponding antibodies can cause FNIAT.  
IMPORTANCE OF RECOMBINANT SOLUBLE 
PLATELET GLYCOPROTEINS IN THE PLATELET 
ANTIBODY IDENTIFICATION  
Timely and accurate testing for alloantibodies 
directed against the HPAs residing on GPIIb is vital for 
clinical diagnosis of FNAIT and to ensure adequate 
blood supply for patients who need allogeneic blood 
transfusions. The advantages of using the recombinant 
soluble platelet glcoproteins (PGPs) are twofold: they 
can be incorporated in the solid-phase assays such as 
ELISA and they are single antigens and hence can be 
used for direct antibody identification [4, 14, 15].
 
Several PGPs have been recombinantly produced and 
used in the solid phase assays [4, 16, 17]. However, 
the attempts to produce the rs GPIIb in 1990s were the 
‘flash- in-the-pan’ that has now fizzled. Production of 
the rs GPIIb would be very interesting and challenging 
first to establish a proof of principle for rs GPIIb 
production, and second to check their suitability for the 
detection not only HPA-3a alloantibodies but also the 
 
Figure 1: The GPIIb/IIIa integrin heterodimer.  
Table 1: Human Platelet Allo-Antigens Expressed on 
Glycoprotein IIb 






I843S FNAIT, PTP, MRP 
HPA-9bw V837M FNAIT 
HPA-20bw T619M FNAIT 
HPA-22bw K164T FNAIT 
HPA-24bw S472N FNAIT 
HPA-27bw L841M FNAIT 
FNIAT, Neonatal alloimmune thrombocytopenia; PTP, post-transfusion 
purpura; MRP, multiple-platelet transfusion refractoriness  
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antibodies directed against the rest of antigens residing 
on GPIIb.  
IIB OR NOT IIB: THE CINDERELLA MOMENT 
(EXPRESSION OF THE RS GPIIB) IS STILL 
DISTANT  
The first study investigating the feasibility of 
producing the rs GPIIb was Bennett et al. 1993 [5]. 
They found that the transfected COS-1 cells with the 
plasmid containing the truncated GPIIb gene could not 
produce the soluble form of GPIIb, and that GPIIb was 
retained and degraded in the ER. They have concluded 
that retention of the soluble GPIIb in the ER might be 
attributed to the presence of a retention signal in the 
extracellular domain of the GPIIb. The study showed 
that the soluble GPIIb failed to undergo endoproteo- 
lysis cleavage into heavy and light chains, however, the 
GPIIb chain cleaves when it is expressed as a soluble 
heterodimer. Because endoproteolysis occurs in the 
Golgi apparatus, this confirms that the soluble GPIIb is 
retained in the ER [18]. The chaperone binding protein 
(BiP) and the intracellular calcium were not responsible 
for the retention of soluble GPIIb [5].  
Cells have normally the Go no Go mechanism that 
orchestrates the transport of well-folded proteins out of 
the ER or retention of the malfolded proteins in the ER 
[19]. Association of the intact extracellular domain of 
the GPIIb with the intact extracellular domain of the 
GPIIIa is a prerequisite for their successful transport as 
a soluble heterdimer to the Golgi bodies. Thus argues 
the notion that the truncated GPIIb is malfolded. The 
soluble heterodimer, however, will not be transported to 
the Golgi apparatus if a part of the light chain of the 
GPIIb is deleted [20]. Therefore, the presence of the 
GPIIIa could not mask the defect in the GPIIb. An 
alternatively spliced truncated form of the GPIIb has 
been identified in human leukemia, prostate 
adenocarcinoma, and melanoma cells but not in the 
platelets or normal prostate epithelial or normal breast 
epithelial cells [21]. This variant consists of the 
extracellular domain (heavy chain and part of the light 
chain) and lacks the transmembrane and cytoplasmic 
domains [21]. It is still unknown how the cancer cells 
can produce this truncated variant of the GPIIb and 
why the normal cells can’t express it. Thus, the 
question of whether the soluble GPIIb monomer can be 
recombinantly produced is still unanswered. 
FUTURE DIRECTIONS 
Expression of the rs GPIIb is still challenging. The 
importance of expression of rs GPIIb would be first a 
proof-of-concept and second the expectations that this 
rs GPIIb would be suitable for antibody identification. 
Therefore, several strategies can still be done in to 
overcome the rs GPIIb retention by the ER and to 
ensure its export to the Golgi apparatus. One model is 
to utilize the lentiviral technology to transduce 
mammalian cells [22]. We have recently showed the 
value of using the lentiviral vector system in the 
expression of large amounts of rs GPIIIa in the human 
embryonic kidney 293 (HEK) cells [4]. In addition, 
multiple approaches have been described for better 
engineering of lentiviral constructs such as using of the 
spleen focus-forming virus (SFFV) promoter, which 
enhances the protein production [23], or addition of 
various DNA elements to the virus [24]. Cotransfection 
with lentiviral vectors expressing chaperone proteins 
might lead to the expression of correctly folded soluble 
GPIIb and its export to the Golgi apparatus. Several 
studies have proved the impact of different protein tags 
on the folding, stability, proteolytic resistance, hydrogen 
bond formation, and solubility of the recombinant 
protein production [4, 25, 26]. Therefore, it is 
worthwhile to add different tags while engineering the 
lentiviral constructs that contain the truncated GPIIb 
gene. Cultivation of the transduced cells under different 
culture conditions might affect on the protein production 
[23]. The alternative spliced truncated GPIIb that has 
been previously determined in different tumor cells [21]
 
is an example of the special machine the tumor cells 
have to create a wide spectrum of proteins. This 
truncated GPIIb could escape the chaperones in the 
ER and the terminator “non-sense mediate mRNA 
decay” [27]. Therefore, transduction of highly 
proliferative tumor cell lines (e.g., K562, prostate 
cancer cells) with the lentiviral vectors containing the 
truncated GPIIb might be a possibility that the rs GPIIb 
would escape the checkpoint in the ER. 
CONCLUSIONS 
The platelet glycoprotein IIb (GPIIb) is an integral 
membrane protein, which forms with GPIIIa a calcium-
dependent heterodimer [1]. All previous attempts to 
produce the rs GPIIb form have failed. The importance 
of expressing the rs GPIIb is that it can be used in the 
solid phase assays for the antibody identification. 
Several pathways such as better vector design, 
transduction of various normal and cancerous 
mammalian cells, or cultivation of transduced cells 
under different conditions can be performed to try to 
overcome the rs GPIIb retention by the ER. Yet, it is 
still challenging and unresolved question whether the 
soluble monomer form of the GPIIb can be produced or 
not and if it would be suitable for the antibody 
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identification. Decryption the code of rs GPIIb 
expression needs to be determined.  
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